Abstract 54P
Background
Disialoganglioside (GD2) is a glycolipid antigen highly expressed in several solid tumors. A chimeric antigen receptor (CAR)-T cell targeting GD2 has been developed and recently showed promising results in clinical trials for neuroblastoma. Previous generations of aGD2-CAR-T cells belong to second—and third-generation CARs, which harbor one and two costimulatory domains within their CAR structures. Incorporation of co-stimulatory domains may help improve CAR T-cell functions. We aim to validate whether incorporating three costimulatory domains within fourth-generation CAR (CAR4) can improve antitumor efficiency against GD2-positive tumors in vitro.
Methods
A fourth-generation CAR containing humanized scFv-GD2, hu3F8, and three costimulatory domains composed of CD28, 4-1BB, and CD27 linked to a CD3 zeta was produced in primary human T cells by using a lentiviral vector system. Two versions of third-generation CAR were also maced (CAR3.1 and CAR3.2 containing co-stimulatory parts of CD28/BB or CD28/CD27, respectively), linked to a CD3z signaling domain. Antitumor activity, CAR-T cell proliferation, and cytokine production were compared between CAR3 and CAR4-T cells against human neuroblastoma and retinoblastoma cell lines.
Results
In vitro, co-culture assays showed that aGD2-CAR4-T exerted superior anti-tumor efficiency than aGD2-CAR3-T cells for killing neuroblastoma. In contrast, these aGD2-CAR-T did not destroy a normal retinal epithelial cell that lacks GD2 expression. However, upon long-term co-culture for 72 h, anti-GD2-CAR4-T showed more excellent cytolytic activities than CAR3-T cells. Interestingly, cytokine production levels, IFN-γ and TNF-α, secreted from anti-GD2-CAR4-T cells were slightly lower than those from CAR3-T cells. We observed that CAR3.2 containing CD27 (CD28/CD27z) had the highest proliferative capacity upon antigen engagement.
Conclusions
Our fourth-generation CAR T-cells targeting GD2 showed superior cytolytic activities than third-generation CAR T-cells against GD2-positive tumor cells in vitro. Anti-GD2-CAR4-T cells will be a promising therapeutic strategy for GD2-positive cancers.
Legal entity responsible for the study
The authors.
Funding
The Office of National Higher Education Science Research and Innovation Policy Council (NXPO) by Program Management Unit-Competitiveness (PMU-C) (grant no. C10F630063).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract